MX359337B - Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. - Google Patents
Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.Info
- Publication number
- MX359337B MX359337B MX2015012063A MX2015012063A MX359337B MX 359337 B MX359337 B MX 359337B MX 2015012063 A MX2015012063 A MX 2015012063A MX 2015012063 A MX2015012063 A MX 2015012063A MX 359337 B MX359337 B MX 359337B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- oligonucletotides
- antisense
- treatment
- stem cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un compuesto para usarse en un método para tratar o suprimir la metástasis de un cáncer en un individuo, donde el compuesto comprende una cantidad efectiva de uno o más oligonucleótidos complementarios a una molécula de ARN mitocondrial quimérico no codificante humano que comprende: a. un ARN ribosómico mitocondrial 16S antisentido enlazado covalentemente en su extremo 5´al extremo 3´de un polinucleótido con una secuencia repetida invertida, o b. un ARN ribosómico mitocondrial 16S sentido enlazado covalentemente en un extremo 5´ al extremo 3´de un polinucleótido con una secuencia repetida invertida, en donde el uno o más oligonucleótidos son capaces de hibridizar con las moléculas de ARN mitocondrial quimérico para formar un dúplex estable, y en donde el individuo previamente ha sido tratado para cáncer con una terapia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361785269P | 2013-03-14 | 2013-03-14 | |
US201361790072P | 2013-03-15 | 2013-03-15 | |
US201461937438P | 2014-02-07 | 2014-02-07 | |
PCT/US2014/029606 WO2014153209A1 (en) | 2013-03-14 | 2014-03-14 | Antisense oligonucletotides for treatment of cancer stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015012063A MX2015012063A (es) | 2016-04-06 |
MX359337B true MX359337B (es) | 2018-07-09 |
Family
ID=51581450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012063A MX359337B (es) | 2013-03-14 | 2014-03-14 | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. |
Country Status (14)
Country | Link |
---|---|
US (3) | US9862944B2 (es) |
EP (1) | EP2970970B1 (es) |
JP (1) | JP6313419B2 (es) |
CN (2) | CN105229150A (es) |
BR (1) | BR112015022308A8 (es) |
CA (1) | CA2906198C (es) |
CL (1) | CL2015002612A1 (es) |
DK (1) | DK2970970T3 (es) |
ES (1) | ES2708650T3 (es) |
HK (1) | HK1220482A1 (es) |
HU (1) | HUE042738T2 (es) |
MX (1) | MX359337B (es) |
PL (1) | PL2970970T3 (es) |
WO (1) | WO2014153209A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014153209A1 (en) | 2013-03-14 | 2014-09-25 | Andes Biotechnologies S.A. | Antisense oligonucletotides for treatment of cancer stem cells |
EP2970364B1 (en) | 2013-03-14 | 2019-04-24 | Andes Biotechnologies Global, Inc. | Methods for detecting and treating multiple myeloma |
KR102145176B1 (ko) * | 2017-11-27 | 2020-08-18 | (주)프로스테믹스 | 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
WO2020206999A1 (zh) * | 2019-04-11 | 2020-10-15 | 北京基石生命科技有限公司 | 胃癌和胆囊胆管癌原代细胞培养方法及配套试剂 |
CN113893261B (zh) * | 2021-06-22 | 2023-01-13 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | circITGB6-ASO与铂类化疗药物联合使用在制备治疗卵巢癌的药物中的应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
DE3851889T2 (de) | 1987-06-24 | 1995-04-13 | Florey Howard Inst | Nukleosid-derivate. |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
JPH0874B2 (ja) | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
KR100211552B1 (ko) | 1990-08-03 | 1999-08-02 | 디. 꼬쉬 | 유전자 발현 억제용 화합물 및 방법 |
CA2092002A1 (en) | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
EP1256589A3 (en) | 1991-11-26 | 2003-09-17 | Isis Pharmaceuticals, Inc. | Oligomers containing modified pyrimidines |
TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
JPH08508491A (ja) | 1993-03-31 | 1996-09-10 | スターリング ウインスロップ インコーポレイティド | ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US8715645B2 (en) | 1994-05-27 | 2014-05-06 | The Regents Of The University Of Colorado | Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same |
DK1003850T3 (da) | 1997-06-06 | 2009-09-07 | Univ California | Inhibitorer af DNA-immunstimulatorisk sekvensaktivitet |
ES2536002T3 (es) | 2003-05-21 | 2015-05-19 | Andes Biotechnologies S.A. | Marcadores para células pre-cancerígenas y cancerígenas y el método para interferir con la proliferación celular en ellas |
EP1938906B1 (en) | 2005-10-20 | 2016-12-07 | Tokuyama Corporation | Method for removing mixed air in coating liquid |
PL1984381T3 (pl) | 2006-01-27 | 2011-03-31 | Isis Pharmaceuticals Inc | Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych |
EP2019692B1 (en) | 2006-05-05 | 2014-06-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of gccr |
EP2192925A4 (en) * | 2007-08-23 | 2013-04-03 | Keren Pharmaceuticals | TARGETING RNA WITH EXTERNAL GUIDE SEQUENCES |
JP2011504106A (ja) | 2007-11-20 | 2011-02-03 | ホピト ユニベルシテレ ドゥ ジュネーブ | 腫瘍由来の癌を引き起こす未成熟細胞または幹細胞の同定、精製および濃縮方法ならびにその使用 |
WO2011031520A1 (en) * | 2009-08-27 | 2011-03-17 | Idera Pharmaceuticals, Inc. | Composition for inhibiting gene expression and uses thereof |
WO2014153209A1 (en) | 2013-03-14 | 2014-09-25 | Andes Biotechnologies S.A. | Antisense oligonucletotides for treatment of cancer stem cells |
EP2970364B1 (en) | 2013-03-14 | 2019-04-24 | Andes Biotechnologies Global, Inc. | Methods for detecting and treating multiple myeloma |
-
2014
- 2014-03-14 WO PCT/US2014/029606 patent/WO2014153209A1/en active Application Filing
- 2014-03-14 DK DK14770117.1T patent/DK2970970T3/en active
- 2014-03-14 MX MX2015012063A patent/MX359337B/es active IP Right Grant
- 2014-03-14 HU HUE14770117A patent/HUE042738T2/hu unknown
- 2014-03-14 ES ES14770117T patent/ES2708650T3/es active Active
- 2014-03-14 CN CN201480026262.3A patent/CN105229150A/zh active Pending
- 2014-03-14 EP EP14770117.1A patent/EP2970970B1/en active Active
- 2014-03-14 CN CN202210729571.3A patent/CN115518073A/zh active Pending
- 2014-03-14 PL PL14770117T patent/PL2970970T3/pl unknown
- 2014-03-14 US US14/775,654 patent/US9862944B2/en active Active
- 2014-03-14 BR BR112015022308A patent/BR112015022308A8/pt not_active Application Discontinuation
- 2014-03-14 JP JP2016503160A patent/JP6313419B2/ja active Active
- 2014-03-14 CA CA2906198A patent/CA2906198C/en active Active
-
2015
- 2015-09-11 CL CL2015002612A patent/CL2015002612A1/es unknown
-
2016
- 2016-07-15 HK HK16108389.4A patent/HK1220482A1/zh not_active IP Right Cessation
-
2017
- 2017-11-29 US US15/826,535 patent/US10457943B2/en active Active
-
2019
- 2019-09-17 US US16/573,983 patent/US11319535B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2970970A4 (en) | 2016-10-19 |
BR112015022308A8 (pt) | 2018-01-23 |
CL2015002612A1 (es) | 2016-08-26 |
EP2970970A1 (en) | 2016-01-20 |
US20180171335A1 (en) | 2018-06-21 |
DK2970970T3 (en) | 2019-02-11 |
CN105229150A (zh) | 2016-01-06 |
WO2014153209A8 (en) | 2015-02-26 |
US20160138015A1 (en) | 2016-05-19 |
CA2906198A1 (en) | 2014-09-25 |
HUE042738T2 (hu) | 2019-07-29 |
PL2970970T3 (pl) | 2019-06-28 |
EP2970970B1 (en) | 2018-12-12 |
HK1220482A1 (zh) | 2017-05-05 |
US9862944B2 (en) | 2018-01-09 |
BR112015022308A2 (pt) | 2017-10-10 |
WO2014153209A1 (en) | 2014-09-25 |
ES2708650T3 (es) | 2019-04-10 |
US10457943B2 (en) | 2019-10-29 |
US20200239885A1 (en) | 2020-07-30 |
JP6313419B2 (ja) | 2018-04-18 |
CN115518073A (zh) | 2022-12-27 |
MX2015012063A (es) | 2016-04-06 |
JP2016519084A (ja) | 2016-06-30 |
US11319535B2 (en) | 2022-05-03 |
CA2906198C (en) | 2022-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
MX2021006531A (es) | Composicion que contiene arn para tratamiento de enfermedades tumorales. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2015008697A (es) | Tratamiento contra la degeneración macular relacionada con la edad. | |
WO2016106400A3 (en) | Rna interference agents for gst-pi gene modulation | |
WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | |
MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
PH12018502569A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX2015015564A (es) | Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos. | |
MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
MX359337B (es) | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. | |
MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
MY178390A (en) | Inhibitors of iap | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
GB2507700A (en) | Compositions and methods for treatment of metastatic cancer | |
MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
PH12014502109A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
NZ744845A (en) | Cancer treatment | |
PH12018502571A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
EA201992441A1 (ru) | Способы лечения с использованием аденовируса |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: ANDES BIOTECHNOLOGIES GLOBAL, INC. |
|
HC | Change of company name or juridical status |
Owner name: ARRIS ENTERPRISES, LLC |
|
FG | Grant or registration |